Showing results (131-140 of 173) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|June 15, 2022
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapyAyalew Tefferi, Naseema Gangat, Aref Al-Kali, et al.
British Journal of Haematology|December 12, 2023
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)Ayalew Tefferi, Farah Fleti, Onyee Chan, et al.
American Journal of Clinical Pathology|August 8, 2022
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined SignificanceDragan Jevremovic, Ahmad Nanaa, Susan M Geyer, et al.
Blood Neoplasia|April 30, 2026
Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experienceJabra Zarka, Clifford M Csizmar, Syeda Mina, et al.
Haematologica|January 8, 2026
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromesMahmood Aldapt, Yu-Hung Wang, Kashish J Shah, et al.
Haematologica|February 1, 2024
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasmsAnmol Baranwal, Mark Gurney, Rami Basmaci, et al.
The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.
Blood Cancer Journal|April 11, 2023
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasmsMithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, et al.
American Journal of Hematology|August 14, 2021
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromesEmma St Martin, Alejandro Ferrer, Abhishek A Mangaonkar, et al.
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
Pageof 18